AbbVie

Recent news

• Company notice
  AbbVie | 4: Statement of changes in beneficial ownership of securities-Officer Michael Robert A.
  SEC · 2026/2/21
• Rating change
  Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $290 to $305
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Company notice
  Haisike: Announcement on Signing a License Agreement for Nav1.8 Inhibitor with AbbVie
  SZSI · 2026/4/13
• Rating change
  BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $300
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• Rating change
  Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $320
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• Rating change
  BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $289
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Rating change
  TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $290 to $310
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• Company notice
  AbbVie | 4: Statement of changes in beneficial ownership of securities-Director Davis Jennifer L.
  SEC · 2026/5/13
• Rating change
  J.P. Morgan Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $285
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $310
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Company notice
  AbbVie | 4: Statement of changes in beneficial ownership of securities-Director BURNSIDE WILLIAM H.L.
  SEC · 2026/5/13
• UBS Maintains AbbVie(ABBV.US) With Hold Rating, Raises Target Price to $275
  \u5e02\u573a\u8d44\u8baf · 2026/10/10
• Rating change
  RBC Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Company notice
  AbbVie | 4: Statement of changes in beneficial ownership of securities-Officer Michael Robert A.
  SEC · 2026/3/4
• Rating change
  A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $280 to $300
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• Rating change
  Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and PepGen Inc. (PEPG)
  TipRanks · 2026/10/8
• BofA Securities Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $305
  \u5e02\u573a\u8d44\u8baf · 2026/10/10
• Rating change
  AbbVie (ABBV) Gets a Buy From J.P. Morgan
  TipRanks · 2026/9/25
• Rating change
  BofA Securities Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $282
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• Rating change
  HSBC Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $315
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• Rating change
  Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Rating change
  BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $282
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• Rating change
  Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $303
  \u5e02\u573a\u8d44\u8baf · 2026/8/20

Headlines are aggregated automatically and are not independently verified or edited by our team.